Contrarily, larger studies have not observed a consistent link between depression and poorer glycemic control in T2DM [14]
Research from ACR Convergence 2025 highlighted GLP-1 receptor agonists as showing particular promise in psoriatic arthritis management, where the dual burden of skin and joint disease creates challenges for conventional therapies
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D
It must be considered that multiple factors interact to control IGF-1 levels, many of which are disturbed in T2D, namely: increased inflammatory cytokines, decreased hepatic insulin action due to resistance, concomitant changes in IGFBPs, and the effects of obesity